Hi, help us enhance your experience
Hi, help us enhance your experience
Hi, help us enhance your experience
1144 Views
eMediNexus 05 December 2017
The first large-scale NIH sponsored clinical trial ‘HPTN 084’ of a long-acting injectable medication for HIV prevention in sexually active women has begun. The study in southern and eastern Africa will examine whether a long-acting form of the investigational anti-HIV drug cabotegravir injected once every eight weeks can safely protect women at risk for HIV infection. The only drug regimen currently licensed for HIV pre-exposure prophylaxis, or PrEP, is the anti-HIV medication Truvada taken daily as an oral tablet.
{{Article_Title}}
{{Article_Author}}
{{Article_Title}}
{{Article_Author}}
{{Article_Title}}..
Detecting Intra-abdominal Adhesions in Women with Repeated C-sections..
Maintaining Liver Health to Optimize Glycemic Outcomes in Early Type 2.....
Antibiotic Prescribing Practices for Pediatric Acute Otitis Media..
Hidden Hazard of Indoor Pollution in COPD..
Recognizing Pitfalls of Point-of-Care Lung Ultrasound..
{{Article_Title}}..
Bombay HC Questions Denial of Motherhood to Woman with Intellectual Disability..
HMPV Outbreak in India: Health Minister Warns of Similar Symptoms to COVID-19, States Prepare Special ICU Wards..
Maharashtra Medical Education Minister Warns Children and Elderly to Stay Alert amid HMPV Cases..
Medical Negligence in Rewa: Surgical Needle Left inside Woman's Abdomen for Two Years..
HMPV in India: Seven Cases Reported across Four States..